ARTICLE | Clinical News
Phase II results for Celgene's Thalomid
May 16, 2001 7:00 AM UTC
In a U.S. Phase II dose escalation trial of CELG's Thalomid thalidomide in 26 patients with metastatic renal cell carcinoma, researchers reported that 16 of 25 evaluable patients (64%) achieved stable...